Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma

Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04970251

Enrollment

Registered

2021-07-21

Start date

2018-11-01

Completion date

2021-03-31

Last updated

2021-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma Secondary to Eye Inflammation, Intraocular Pressure, Neovascular Glaucoma, Vascular Endothelial Growth Factor Overexpression

Brief summary

Purpose: To investigate intravitreal aflibercept (IVA) injection as an adjunctive treatment to trabeculectomy with mitomycin C (TMC) and panretinal photocoagulation (PRP) for neovascular glaucoma (NVG). Setting: Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand Study design: Prospective interventional case series Methods: PRP and IVA (2 mg/0.05 ml) injection were given, and TMC was performed within 2 weeks after IVA. Additional PRP, laser suture lysis, subconjunctival 5-fluorouracil injection, and bleb needling were performed after TMC if indicated. Best-collected visual acuity (BCVA), intraocular pressure (IOP), surgical complications, and number of anti-glaucoma medications were collected.

Interventions

DRUGAflibercept Ophthalmic

Panretinal photocoagulation and intravitreal aflibercept (2 mg/0.05 ml) injection were given, and trabeculectomy with mitomycin C was performed within 2 weeks after intravitreal aflibercept injection.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Consecutive patients with neovascular glaucoma who presented at the Department of Ophthalmology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand during November 2018 to October 2019. * Aged more than 18 year-old

Exclusion criteria

* Patients who received any anti-vascular endothelial growth factor treatment before participation

Design outcomes

Primary

Measure	Time frame	Description
Intraocular pressure	Post-operative on day 1st	Intraocular pressure after trabeculectomy

Secondary

Measure	Time frame	Description
Numbers of medication	Post-operative on month12th	Numbers of anti-glaucoma medications
Visual acuity	Post-operative on day 1st	Visual acuity of the studied eye

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026